Limits...
Utility of epirubicin-incorporating micelles tagged with anti-tissue factor antibody clone with no anticoagulant effect.

Sugaya A, Hyodo I, Koga Y, Yamamoto Y, Takashima H, Sato R, Tsumura R, Furuya F, Yasunaga M, Harada M, Tanaka R, Matsumura Y - Cancer Sci. (2016)

Bottom Line: In vitro, all forms of anti-TF1859-NC-6300 showed higher cytocidal effects than NC-6300 in BxPC3, whereas this enhanced effect was not observed in SUIT2.Likewise, all forms of anti-TF1859-NC-6300 significantly suppressed tumor growth when compared to NC-6300 in the BxPC3, but not in the SUIT2, xenograft model.Thus, we have confirmed an enhanced antitumor effect of anti-TF1859-NC-6300 in a TF-high expressing tumor; anti-TF1859-IgG-NC-6300 could be used to simplify the manufacturing process of the antibody-micelle conjugation for future clinical studies.

View Article: PubMed Central - PubMed

Affiliation: Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Show MeSH

Related in: MedlinePlus

Comparative binding activities were determined with flow cytometry analysis among anti‐TF1859‐NC‐6300 using BxPC3 (tissue factor [TF]‐high expressing) and SUIT2 (TF‐low expressing) pancreatic cancer cells.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4814265&req=5

cas12863-fig-0002: Comparative binding activities were determined with flow cytometry analysis among anti‐TF1859‐NC‐6300 using BxPC3 (tissue factor [TF]‐high expressing) and SUIT2 (TF‐low expressing) pancreatic cancer cells.

Mentions: Binding affinities of three formulations of anti‐TF‐NC‐6300 conjugated with 1859 IgG, F(ab’)2, and Fab’ were almost the same as that of anti‐TF mAb in BxPC3. The binding activities of the three formulations of anti‐TF1859‐NC‐6300 and anti‐TF1859 mAb to BxPC3 were approximately 10‐fold higher than that to SUIT2. Otherwise, no significant differences were observed in terms of the binding activities of IgG, F(ab’)2, and Fab’ to BxPC3, whereas the affinities of anti‐TF (IgG, F[ab’]2, and Fab’)‐NC‐6300 and NC‐6300 were almost the same in the SUIT2 cell line (Fig. 2).


Utility of epirubicin-incorporating micelles tagged with anti-tissue factor antibody clone with no anticoagulant effect.

Sugaya A, Hyodo I, Koga Y, Yamamoto Y, Takashima H, Sato R, Tsumura R, Furuya F, Yasunaga M, Harada M, Tanaka R, Matsumura Y - Cancer Sci. (2016)

Comparative binding activities were determined with flow cytometry analysis among anti‐TF1859‐NC‐6300 using BxPC3 (tissue factor [TF]‐high expressing) and SUIT2 (TF‐low expressing) pancreatic cancer cells.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4814265&req=5

cas12863-fig-0002: Comparative binding activities were determined with flow cytometry analysis among anti‐TF1859‐NC‐6300 using BxPC3 (tissue factor [TF]‐high expressing) and SUIT2 (TF‐low expressing) pancreatic cancer cells.
Mentions: Binding affinities of three formulations of anti‐TF‐NC‐6300 conjugated with 1859 IgG, F(ab’)2, and Fab’ were almost the same as that of anti‐TF mAb in BxPC3. The binding activities of the three formulations of anti‐TF1859‐NC‐6300 and anti‐TF1859 mAb to BxPC3 were approximately 10‐fold higher than that to SUIT2. Otherwise, no significant differences were observed in terms of the binding activities of IgG, F(ab’)2, and Fab’ to BxPC3, whereas the affinities of anti‐TF (IgG, F[ab’]2, and Fab’)‐NC‐6300 and NC‐6300 were almost the same in the SUIT2 cell line (Fig. 2).

Bottom Line: In vitro, all forms of anti-TF1859-NC-6300 showed higher cytocidal effects than NC-6300 in BxPC3, whereas this enhanced effect was not observed in SUIT2.Likewise, all forms of anti-TF1859-NC-6300 significantly suppressed tumor growth when compared to NC-6300 in the BxPC3, but not in the SUIT2, xenograft model.Thus, we have confirmed an enhanced antitumor effect of anti-TF1859-NC-6300 in a TF-high expressing tumor; anti-TF1859-IgG-NC-6300 could be used to simplify the manufacturing process of the antibody-micelle conjugation for future clinical studies.

View Article: PubMed Central - PubMed

Affiliation: Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Show MeSH
Related in: MedlinePlus